| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Annexuzlimab (MDX-124) (2.5-10 μM; 72 hours) significantly inhibited the proliferation of human cancer cell lines expressing ANXA1 in a dose-dependent manner. Among them, 10 μM reduced the survival rate of some breast cancer and ovarian cancer cell lines by more than 50%, but had no effect on lung cancer cell lines that do not express ANXA1 [1]. Annexuzlimab (10-25 μM; 24 hours) induced G1 phase cell cycle arrest in a dose-dependent manner. Among them, 25 μM had the most significant effect (G1 phase arrest increased by 33.5% in MDA-MB-231 cells, 21.2% in A549 cells, and 10.8% in BxPC-3 cells), and did not induce apoptosis [1]. Annexuzlimab (5 μM; 72 hours) did not induce apoptosis in MCF-7 breast cancer cells or Caco-2 colorectal cancer cells [1]. Annexuzlimab incubation of osteosarcoma cell lines significantly inhibits cell growth through dose-dependent cell cycle arrest and also significantly reduces the migration ability of osteosarcoma cell lines[2].
|
|---|---|
| ln Vivo |
Annexuzlimab (1 mg/kg; intravenous injection; once on day 1 and once on day 8) inhibited tumor growth in a BALB/c triple-negative breast cancer mouse model (tumor growth inhibition rate of 23%) [1].
|
| Animal Protocol |
Animal/Disease Models:BALB/c (female, 9 weeks old, orally inoculated with 4T1-luc mouse triple-negative breast cancer cells) [1]
Doses: 1 mg/kg Route of Administration: Intravenous injection; administered once on day 1 and once on day 8 Experimental Results: Compared with the vector control group, tumor growth was significantly inhibited, with a tumor growth inhibition rate of 23% by day 15. No significant changes in body weight were observed throughout the study. |
| References |
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| Synonyms |
MDX-124
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
